Why focus matters
Not all women's health innovations face the same translation barriers. The platform prioritises conditions where the gap between strong science and investable ventures is widest — and where specialist support has the most leverage.
Focus areas are informed by unmet clinical need, research maturity in Australian institutions, and the specific translation challenges each condition presents.
Focus area overview
Seven priority areas where the platform concentrates expertise, evidence frameworks, and strategic partnerships.
Endometriosis and pelvic pain
Affects 1 in 9 Australian women. Diagnostic delay averages 6.5 years. Endpoints are subjective and heterogeneous, trial recruitment is fragmented, and reimbursement pathways for non-surgical interventions are underdeveloped.
Translation challenge: No universally accepted biomarker — making non-invasive diagnostic development dependent on endpoint choices that determine the entire regulatory pathway. TGA classification (screening tool vs diagnostic device) dictates evidence requirements from day one.
Fertility and reproductive health
IVF and assisted reproduction are well-established, but innovations in fertility preservation, ovarian biology, and male-factor contributions face longer evidence pathways and market-sizing challenges unique to the category.
Translation challenge: Reimbursement varies dramatically by state and insurance structure. Market sizing is complicated by elective vs medically indicated framing, and trial recruitment faces patient sensitivity and timing constraints unique to reproductive biology.
Maternal and perinatal health
Pre-eclampsia, gestational diabetes, and preterm birth carry significant morbidity and cost. Interventions face complex trial design (dual maternal-fetal endpoints), regulatory conservatism, and implementation barriers in diverse health systems.
Translation challenge: Dual maternal-fetal endpoints create regulatory complexity. Hospital procurement decisions are made by committees, not individual clinicians, and clinical workflow integration must account for diverse care settings from tertiary centres to regional hospitals.
Menopause and midlife health
The fastest-growing demographic in women's health with underserved clinical needs across vasomotor symptoms, cardiovascular risk, bone health, and cognitive decline. Historical stigma has left evidence and commercial infrastructure thin.
Translation challenge: The $1.7T global women’s health market opportunity (McKinsey, 2024) is disproportionately concentrated here. Regulatory frameworks for digital interventions are still being written, and the evidence bar for payer acceptance remains unclear for non-pharmacological approaches.
Gynaecological cancers
Ovarian, cervical, and uterine cancers with active innovation in early detection, targeted therapies, and survivorship care. Evidence pathways are clearer but adoption and equitable access remain structural barriers.
Translation challenge: Evidence pathways are better defined than other focus areas, but adoption depends on screening program integration (cervical), surgical workflow changes (ovarian), and survivorship care models that cross primary and specialist settings.
Pelvic floor and continence
High prevalence, low prioritisation. Digital and device-based innovations face reimbursement and adoption challenges compounded by stigma and fragmented clinical pathways.
Translation challenge: Device classification determines whether TGA or MSAC is the primary gatekeeper. Consumer health products face the additional challenge of demonstrating clinical-grade evidence in a category where most existing solutions are unregulated.
Reproductive and hormonal conditions
PCOS, adenomyosis, and hormonal disorders with complex, overlapping presentations. Evidence bases are thin relative to prevalence, and regulatory endpoints are evolving.
Translation challenge: Overlapping presentations mean trial cohorts are hard to define cleanly. PCOS affects 8–13% of women of reproductive age but has no single diagnostic standard, making endpoint selection and comparator choice critical early decisions.
This is not a closed list
These areas reflect current priorities based on unmet need, Australian research strengths, and translation feasibility.
The platform will consider innovations outside these areas where the women's health translation case is compelling and the evidence path is credible.
Final scope and selection criteria are subject to program settings as they are confirmed.